ClinicalTrials.gg
WithdrawnNCT07213843CDINUpdated Nov 10, 2026

Combined Circulatory and Dietary Interventions for Neuropathy

An interventional study of INF® Therapy and NVIf in Diabete Type 2 and Neuropathy, Painful, sponsored by Loma Linda University. Withdrawn at 1 site in United States. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Loma Linda University · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Study was never initiated/no study participants were ever enrolled/study was never funded.
Updated Nov 10, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,889th of 2,961
0 · median 90
Started
2026
with 157 others
No phase
1,242 of 3,308
200 open now
Registered
3,136th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,889th largest by enrollment of the 2,961 interventional ones that give a count, is one of 158 that started in 2026, is one of 1,242 with no phase, and was the 3,136th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of three different interventions in improving neuropathy symptoms in individuals aged 35-85 with moderate to severe neuropathy. The study will compare three treatment groups: Intraneural Facilitation® (INF®) therapy alone, INF® therapy combined with Neuro vascular index (NVI) food-guided elimination (NVIf), and NVIf alone. The aim is to determine which treatment results in the greatest improvement in neuropathy symptoms, including quality of life, sensory and pain improvements, and functional outcomes.

Read the detailed description

The purpose of this investigator-initiated study is to observe the effectiveness of a manual physical therapy technique known as Intraneural Facilitation (INF®), both independently and in combination with a Nutritional Vascular Inflammation focused (NVIf) dietary intervention, in improving neurovascular function, pain, and physical performance in individuals with moderate to severe peripheral neuropathy (PN). Subjects will be randomized into one of the three interventions arms: (1) INF® therapy alone, (2) NVIf intervention alone or (3) a combination of both. INF® is a manual therapy, while NVIf utilizes ultrasound guided food elimination. Outcomes include pain (Visual analog scale), sensory function (Semmes Weinstein Monofilament), physical function (Lower extremity functional scale, 10-meter walk test, timed up and go) quality of life (Norfolk Quality of life-Diabetic neuropathy), and neurovascular blood flow analysis. Study participants will be 35-85 years old with a physician-confirmed diagnosis of moderate to severe lower extremity peripheral neuropathy and at least one symptom: numbness, tingling, burning, sharp pain, or increased sensitivity. They must score 0-60 on the Lower Extremity Functional Scale (LEFS), speak and understand English, provide written informed consent, and be willing to complete all study procedures, including intervention and follow-up visits. Participants must be able to ambulate independently with or without an assistive device. Subjects will be recruited using email and flyer through the Neuropathic Therapy Center (NTC) research interest list and through providers at Loma Linda's University (LLU) Health offices. 60 subjects will be recruited, and consent will take place at the LLU or at the Murrieta study site prior to randomization, administered by trained study staff authorized to obtain informed consent.

03

Conditions studied

  • Diabete Type 2
  • Neuropathy, Painful

Keywords

  • neuropathy
  • diabetes type 2
04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of peripheral neuropathy in the lower extremities by a physician
  • Lower Extremity Functional Scale (LEFS) score between 0-60 (indicating moderate to significant difficulty in lower extremity function)
  • Ability to speak and understand English
  • Ability to provide appropriate written
  • Willingness to participate in all study procedures, including the intervention and follow-up visits
  • Ability to ambulate independently with or without an assistive device

Exclusion criteria

Exclusion Criteria

  • Any medical condition suggesting potential decline in function over the next 6 months (e.g., ongoing chemotherapy, radiation therapy, or dialysis)
  • Active alcohol or drug misuse
  • End-stage renal failure
  • Uncontrolled hypertension
  • Severe dyslipidemia
  • Chronic liver disease
  • disease
  • Advanced (COPD)
  • Active inflammation
  • Shingles-related neuropathy
  • Presence of any lower extremity amputations or significant wounds
  • Severe chronic medical conditions requiring active treatment that could interfere with study outcomes
  • Morbid obesity
  • Concomitant use of medications or devices that may interfere with study results or are not allowed per protocol
  • Inability to comprehend or provide
  • Inability to speak or understand English
  • Pregnancy, breastfeeding, or planning pregnancy during the study period (female participants)
  • Inability or unwillingness to adhere to study procedures, including dietary guidelines or follow-up visits
  • Inability to complete all required study assessments, including follow-up appointments and questionnaires
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    INF® Therapy Only Group

    INF® therapy is a manual technique designed to improve neural circulation by using a series of manual holds administered by a trained practitioner. Participants will receive 60-minute sessions, 2-3 times per week, for a total of 8 sessions.

    Other: INF® Therapy

  • Experimental
    NVIf Only Group

    NVIf, is a dietary intervention that uses a patented ultrasound technology to assess vascular responses to food allergens. By identifying foods that exacerbate inflammation and restrict circulation, the intervention guides patients to eliminate these foods, thereby improving nerve health. Those in this group will participate in follow-up for food elimination adherence, including daily tracking of foods ingested. Week 1-2: 4 x NVI food guided-elimination visits. Week 2-5 complete weekly Likert scale inquiring about food eliminations and weekly phone call check-in attempts will be made by research staff.

    Other: NVIf

  • Experimental
    INF® Therapy + NVIf Group

    INF® therapy and NVI Food-Guided Elimination Group: Week 1-2: 4 x NVI food guided-elimination visits. Participants will receive 60-minute sessions, 2-3 times per week, for a total of 8 sessions. As well as participate in NVIf, which is a dietary intervention that uses a patented ultrasound technology to assess vascular responses to food allergens. By identifying foods that exacerbate inflammation and restrict circulation, the intervention guides patients to eliminate these foods, thereby improving nerve health. Those in this group will participate in follow-up for food elimination adherence, including daily tracking of foods ingested. Week 2-5 complete weekly Likert scale inquiring about food eliminations and weekly phone call check-in attempts will be made by research staff as well as INF® therapy for 60-minute sessions, 2-3 times per week, for a total of 8 sessions.

    Other: INF® Therapy · Other: NVIf

Interventions

  • OtherINF® Therapy

    INF® therapy is a manual technique designed to improve neural circulation by using a series of manual holds administered by a trained practitioner,

    Also known as: Intranerual Facilitation

  • OtherNVIf

    NVIf is a dietary intervention that uses a patented ultrasound technology to assess vascular responses to food allergens

    Also known as: Neuro vascular index food-guided elimination

06

What researchers measure

Primary outcomes

  1. Change in Pain Intensity

    Pain intensity will be assessed using the Visual Analog Scale. Improvement will be indicated by reduced VAS scores. Unit of Measure: Millimeters on a 0-100 mm scale.

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

  2. Change in Sensory Function

    Sensory function will be assessed using the Semmes-Weinstein Monofilament test. Improvement will be indicated by increased monofilament detection. Detection threshold in grams (monofilament response: detected/not detected)

    Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)

  3. Change in Functional Limitation

    Functional limitation related to neuropathy will be assessed using the Lower Extremity Functional Scale. Improvement will be indicated by higher Lower Extremity Functional Scale scores. Scale score (0-80).

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

  4. Change in Gait Speed

    Gait speed will be assessed using the 10-Meter Walk Test. Improvement will be indicated by faster walk time. Seconds to complete 10 meters (converted to meters/second if applicable)

    Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)

  5. Change in Mobility and Fall Risk

    Mobility and fall risk will be assessed using the Timed Up and Go (TUG) test. Improvement will be indicated by shorter completion times. Unit of Measure: Seconds.

    Time frame: Baseline (Week 0), mid-treatment (Week 3), and post-intervention (Week 4-5)

Secondary outcomes

  1. Change in Quality of Life

    Quality of life will be measured using the Norfolk Quality of Life-Diabetic Neuropathy questionnaire to determine the effect of each treatment approach on overall patient well-being. Higher scores indicate greater impairment; a reduction reflects improved quality of life. Lowest score=0, means best quality of life with little to no neuropathy impacts. A maximum score of 138, means worst quality of life with severe impairments.

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

Other outcomes

  1. Change in Neurovascular Function and Inflammation

    Mechanistic analysis will be performed using the Neurovascular Index with Philips Affinity 50 Ultrasound to evaluate changes in microvascular resistance and neurovascular blood flow, as well as the effect of NVI-guided food elimination on reducing neurovascular inflammation.

    Time frame: Baseline (Week 0) and post-intervention (Week 4-5)

07

Study locations

1 site
  • Neuropathic Therapy Center
    Loma Linda, California 92354-0200, United States
08

References and documents

Individual participant data

Plan to share: No — No plan to share individual participant data (IPD). De-identified aggregate data may be made available upon reasonable request to the Principal Investigator, following study completion and publication of primary results, in accordance with institutional policies and IRB approval.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 9, 2025
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Study was never initiated/no study participants were ever enrolled/study was never funded.
changed Nov 10, 2026
Enrollment
60 (estimated)→0 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Withdrawn
    Why stopped Study was never initiated/no study participants were ever enrolled/study was never funded.
    Enrollment 60 (estimated)→0 (actual)
    + 3 other changes: verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07213843
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Kyan Sahba, PhD
principal investigator · Loma Linda University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion